L3VLUP
ProSign in

TNGX · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TNGXLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TNGX
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterTNGXLLY
Q3 2020none listed holders, n.a.33 holders, $14.1bn
Q4 2020none listed holders, n.a.29 holders, $17.3bn
Q1 2021none listed holders, n.a.24 holders, $23.0bn
Q2 2021none listed holders, n.a.24 holders, $27.8bn
Q3 20212 holders, $10m31 holders, $29.9bn
Q4 20212 holders, $8.8m31 holders, $34.7bn
Q1 20222 holders, $6.1m24 holders, $35.3bn
Q2 20222 holders, $3.6m33 holders, $42.7bn
Q3 20222 holders, $2.9m31 holders, $43.4bn
Q4 20222 holders, $4.6m31 holders, $46.6bn
Q1 20231 holders, $1.4m33 holders, $44.3bn
Q2 20231 holders, $875k37 holders, $59.6bn
Q3 20231 holders, $2.8m44 holders, $67.6bn
Q4 2023none listed holders, n.a.45 holders, $73.6bn
Q1 2024none listed holders, n.a.41 holders, $95.3bn
Q2 20241 holders, $3.0m43 holders, $110bn
Q3 2024none listed holders, n.a.45 holders, $107bn
Q4 20241 holders, $12m46 holders, $93.9bn
Q1 20251 holders, $6.3m42 holders, $98.4bn
Q2 20252 holders, $78m43 holders, $93.2bn
Q3 20253 holders, $166m39 holders, $86.7bn
Q4 20253 holders, $252m41 holders, $123bn
Q1 20265 holders, $570m39 holders, $106bn
Q2 20265 holders, $805m44 holders, $132bn
TNGX

Tango Therapeutics Inc

Holders
1
Reported value
$12m
Buyers
1
Sellers
0

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations
LLY

Eli Lilly & Co

Holders
46
Reported value
$93.9bn
Buyers
24
Sellers
23

Breadth +1 among 94 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2024

Among the 47 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Both (0)

No tracked manager lists every one of them.

Only TNGX (1)

Farallon Capital Management LLC

Only LLY (46)

Acadian Asset Management LLC, AllianceBernstein LP, AQR Capital Management LLC, Artisan Partners LP, Balyasny Asset Management LLC, Brevan Howard Capital Management LP, Bridgewater Associates LP, Capital Research Global Investors, Capital World Investors, Citadel Advisors LLC, Coatue Management LLC, D. E. Shaw & Co., Dodge & Cox, Egerton Capital UK LLP, Eisler Capital Management Ltd, Fidelity (FMR LLC), Freestone Grove Partners LP, GAMCO Investors Inc, Holocene Advisors LP, Hudson Bay Capital Management LP, Invesco Ltd, Jane Street Group LLC, Janus Henderson Group Ltd, Lone Pine Capital LLC, Man Group PLC, and 21 more

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →